Foghorn Therapeutics Inc. expected to post a loss of 34 cents a share - Earnings Preview

Foghorn Therapeutics

02/05/2025 14:49

Foghorn Therapeutics Inc. FHTX.OQ FHTX.O is expected to show a rise in quarterly revenue when it reports  results on May 5 (estimated) for the period ending March 31 2025

The Cambridge Massachusetts-based  company is expected to report a 15.2% increase in revenue to $5.816 million from $5.05 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Foghorn Therapeutics Inc. is for a loss of 34 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $10.00​, above​ its last closing price of $4.16. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.27
-0.33
-0.30
Beat
8.3
Sep. 30 2024
-0.42
-0.44
-0.31
Beat
29.6
Jun. 30 2024
-0.63
-0.65
-0.45
Beat
31.3​
Mar. 31 2024
-0.56
-0.63
-0.59
Beat
6.9
​​Dec. 31 2023
-0.94
-0.76
-0.57
Beat
25.3
Sep. 30 2023
-0.74
-0.75
-0.34
Beat
54.7​
Jun. 30 2023
-0.74
-0.73
-0.70
Beat
4.8
Mar. 31 2023
-0.68
-0.72
-0.73
Missed
-0.7

This summary was machine generated May 2 at 13:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)